NASDAQ INMB
 

 

Pipeline

Therapies that Target the INNATE IMMUNE Response

 

DN-TNF PlatformDisease FieldPre-clinicalPhase IPhase II (POC)Pivotal
Mild Alzheimer’s Disease CNS
XPRO™
Mild AD
     
MCI
XPRO™
Mild Cognitive Impairment
     
Treatment Resistant Depression
XPRO™
NIH logo
Treatment
Resistant Depression
     
NK-Priming PlatformDisease FieldPre-clinicalPhase IPhase II (POC)Pivotal
Inmune Bio for High-Risk MDS
INKmune™
Myelodysplastic Syndrome
ONCOLOGY
     
Inmune Bio for High-Risk MDS
INKmune™
Ovarian Cancer
     

INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm EST